These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20628214)

  • 1. [Toxicogenomics Project and drug safety evaluation.].
    Urushidani T
    Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):46-9. PubMed ID: 20628214
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics in drug discovery and development -- making an impact.
    Wills Q; Mitchell C
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():33-7. PubMed ID: 19807202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.
    Blomme EA; Yang Y; Waring JF
    Toxicol Lett; 2009 Apr; 186(1):22-31. PubMed ID: 18996174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Toxicogenomics as a tool for evaluation of chemical effects].
    Watanabe H
    Yakugaku Zasshi; 2007 Dec; 127(12):1967-74. PubMed ID: 18057786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in toxicogenomics.
    Hayes KR; Bradfield CA
    Chem Res Toxicol; 2005 Mar; 18(3):403-14. PubMed ID: 15777080
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathway analysis tools and toxicogenomics reference databases for risk assessment.
    Ganter B; Zidek N; Hewitt PR; Müller D; Vladimirova A
    Pharmacogenomics; 2008 Jan; 9(1):35-54. PubMed ID: 18154447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Gene Expression Profiling from Tissue Samples to Support Drug Safety Assessments.
    Stiehl DP; Tritto E; Chibout SD; Cordier A; Moulin P
    ILAR J; 2017 Jul; 58(1):69-79. PubMed ID: 28575330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Literature optimized integration of gene expression for organ-specific evaluation of toxicogenomics datasets.
    Taškova K; Fontaine JF; Mrowka R; Andrade-Navarro MA
    PLoS One; 2019; 14(1):e0210467. PubMed ID: 30640953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The introduction of toxicogenomics; potential new markers of hepatotoxicity.
    Heijne WH; Stierum RH; Leeman WR; van Ommen B
    Cancer Biomark; 2005; 1(1):41-57. PubMed ID: 17192031
    [No Abstract]   [Full Text] [Related]  

  • 12. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery.
    Fostel JM
    Pharmacogenomics; 2007 May; 8(5):425-30. PubMed ID: 17465705
    [No Abstract]   [Full Text] [Related]  

  • 13. Value of new biomarkers for safety testing in drug development.
    Hewitt P; Herget T
    Expert Rev Mol Diagn; 2009 Sep; 9(6):531-6. PubMed ID: 19731999
    [No Abstract]   [Full Text] [Related]  

  • 14. Open TG-GATEs: a large-scale toxicogenomics database.
    Igarashi Y; Nakatsu N; Yamashita T; Ono A; Ohno Y; Urushidani T; Yamada H
    Nucleic Acids Res; 2015 Jan; 43(Database issue):D921-7. PubMed ID: 25313160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of toxicogenomics in drug development.
    Gant TW
    Drug News Perspect; 2003 May; 16(4):217-21. PubMed ID: 12942151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicogenomics in drug safety assessment.
    Hewitt P; Walijew A
    Pharmacogenomics; 2008 Apr; 9(4):379-82. PubMed ID: 18384252
    [No Abstract]   [Full Text] [Related]  

  • 17. Speed and safety in drug discovery: a brief conference report.
    Bhogal N
    Altern Lab Anim; 2009 Feb; 37(1):143-5. PubMed ID: 19370810
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of the comparison approach to open TG-GATEs: A useful toxicogenomics tool for detecting modes of action in chemical risk assessment.
    Heusinkveld HJ; Wackers PFK; Schoonen WG; van der Ven L; Pennings JLA; Luijten M
    Food Chem Toxicol; 2018 Nov; 121():115-123. PubMed ID: 30096367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.
    Verbist B; Klambauer G; Vervoort L; Talloen W; ; Shkedy Z; Thas O; Bender A; Göhlmann HW; Hochreiter S
    Drug Discov Today; 2015 May; 20(5):505-13. PubMed ID: 25582842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.